MS Australia, together with Multiple Sclerosis organisations from Canada, Denmark, France, Germany, Italy, MS International Federation, Spain, U.K., and the U.S. have jointly declared their collective commitment to a global research strategy to cure MS.

MS Australia has today launched a new campaign at Parliament House on World MS Day (30 May) to raise awareness of the crucial role played by MS Nurses.

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of natalizumab (Tysabri®) pre-filled syringe for subcutaneous (under the skin) injection on the Pharmaceutical Benefit Scheme (PBS).

CEO Rohan Greenland shares an update on The May 50K, thanking participants for their significant contributions. He then unveils MS Australia's plans to champion the invaluable role of MS Nurses on World MS Day.

Australian scientists have found new immune-suppressing molecules produced in response to UV exposure that may explain how UV protects from multiple sclerosis.

Clinical Trials Day is an opportunity to express our gratitude to the researchers, clinicians, and nurses who dedicate their lives to advancing medical knowledge and improving patient care. We thank them for their tireless efforts in conducting ground-breaking research and for their commitment to finding new and innovative treatments. Their work is essential for improving health outcomes for people around the world, and we are grateful for their dedication and contributions.